التفاصيل البيبلوغرافية
| العنوان: |
Personalized rheumatic medicine through dose reduction reduces the cost of biological treatment - a retrospective intervention analysis. |
| المؤلفون: |
Meyer, MK, Andersen, M, Ring, T, Andersen, GN, Ehlers, LH, Rasmussen, C, Stensballe, A, Meyer, M K, Andersen, G N, Ehlers, L H |
| المصدر: |
Scandinavian Journal of Rheumatology; Sep2019, Vol. 48 Issue 5, p398-407, 10p, 1 Chart, 4 Graphs |
| مصطلحات موضوعية: |
INDIVIDUALIZED medicine, COST control, RETROSPECTIVE studies, THERAPEUTICS, MEDICAL economics, PSORIATIC arthritis, ANTIRHEUMATIC agents, DOSE-effect relationship in pharmacology, FORECASTING, LONGITUDINAL method, MEDICAL care costs, RHEUMATOID arthritis, DISEASE progression |
| مستخلص: |
Objective: The effects of a dose-reduction intervention of biological disease-modifying anti-rheumatic drugs (bDMARDs) in patients in remission were analysed with epidemiology and health economics strategies. The aims were to analyse changes in bDMARD dosage, evaluate potential disease worsening, and estimate cost reduction. Method: This uncontrolled single-centre observational study analysed bDMARD-treated patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthritis (SpA). bDMARD expenditure constituted a proxy for bDMARD doses, which enabled group-level analysis. Interrupted time-series regression was used to analyse changes in treatment cost due to the dose reduction. Disease activity and treatment durations were monitored to investigate disease worsening. Results: In total, 997 biological treatment cases were analysed. This involved 527 bDMARD patients, where an unknown fraction of patients was given reduced doses. Disease activity of RA and PsA patients decreased from 2001 to 2009 and remained stable after that, while disease activity for SpA patients was unchanged, indicating no disease worsening from the intervention. The dose tapering resulted in decreased bDMARD expenditure, indicating a decrease in bDMARD consumption, which led to an accumulated cost reduction of 4 178 000 EUR. Conclusions: The results suggest that dose reduction can be safely performed in patients in treatment remission on a group level without compromising treatment efficacy. Subcutaneous bDMARDs, including abatacept, adalimumab, and etanercept, were observed to be well suited to customizing dosage. This study highlights the potential for individualized and personalized rheumatic medicine by providing dose reduction to individual patients, while monitoring disease activity. [ABSTRACT FROM AUTHOR] |
|
Copyright of Scandinavian Journal of Rheumatology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
PDF full text from Publisher